TY - JOUR
TI - MUC5B promoter variant rs35705950 and rheumatoid arthritis associated
interstitial lung disease survival and progression
AU - Juge, Pierre-Antoine
AU - Solomon, Joshua J.
AU - van Moorsel, Coline H.
AU - M.
AU - Garofoli, Romain
AU - Lee, Joyce S.
AU - Louis-Sydney, Fabienne and
AU - Rojas-Serrano, Jorge
AU - Gonzalez-Perez, I, Montserrat
AU - Mejia, Mayra
AU - and Buendia-Roldan, Ivette
AU - Falfan-Valencia, Ramces and
AU - Ambrocio-Ortiz, Enrique
AU - Manali, Effrosyni
AU - Papiris, Spyros A. and
AU - Karageorgas, Theofanis
AU - Boumpas, Dimitrios
AU - Antoniou, Katarina M.
AU - and Sidiropoulos, Prodromos
AU - Trachalaki, Athina
AU - Van der Vis,
AU - Joanne J.
AU - Jamnitski, Anna
AU - Grutters, Jan C.
AU - Kannengiesser,
AU - Caroline
AU - Borie, Raphael
AU - Kawano-Dourado, Leticia and
AU - Wemeau-Stervinou, Lidwine
AU - Flipo, Rene-Marc
AU - Nunes, Hilario and
AU - Uzunhan, Yurdagul
AU - Valeyre, Dominique
AU - Saidenberg-Kermanac'h,
AU - Nathalie
AU - Boissier, Marie-Christophe
AU - Richez, Christophe and
AU - Schaeverbeke, Thierry
AU - Doyle, Tracy
AU - Wolters, Paul J.
AU - Debray,
AU - Marie-Pierre
AU - Boileau, Catherine
AU - Porcher, Raphael
AU - Schwartz,
AU - David A.
AU - Crestani, Bruno
AU - Dieude, Philippe
JO - Seminars in Arthritis and Rheumatism
PY - 2021
VL - 51
TODO - 5
SP - 996-1004
PB - W B SAUNDERS CO-ELSEVIER INC
SN - 0049-0172
TODO - 10.1016/j.semarthrit.2021.07.002
TODO - Rheumatoid Arthritis; Interstitial Lung Disease; MUC5B; Genetics
TODO - Background: The major risk factor for idiopathic pulmonary fibrosis
(IPF), MUC5B rs35705950, was found to be associated with rheumatoid
arthritis-associated interstitial lung disease (RA-ILD). Whilst the
MUC5B rs35705950 T risk allele has been associated with better survival
in IPF, its impact on RA-ILD prognosis remains to be determined. Our
objective was to explore the influence of MUC5B rs35705950 on survival
and progression in RA-ILD. Methods: Through an international
retrospective observational study, patients with RA-ILD were genotyped
for the MUC5B rs35705950 variant and consecutive pulmonary function
tests (PFTs) findings were collected. Longitudinal data up to a 10-year
follow-up were considered and analyzed using mixed regression models.
Proportional hazards and joint proportional hazards models were used to
analyze the association of baseline and longitudinal variables with lung
transplant-free survival. Significant progression of RA-ILD was defined
as at least an absolute or relative 10% decline of forced vital
capacity at 2 years from baseline. Results: Out of 321 registered
patients, 261 were included in the study: 139 women (53.3%), median age
at RA-ILD diagnosis 65 years (interquartile range [IQR] 57 to 71), 151
ever smokers (59.2%). Median follow-up was 3.5 years (IQR 1.3 to 6.6).
Mortality rate was 32% (95%CI 19 to 42) at 10 years. The MUC5B
rs35705950 variant did not impact lung transplant-free survival (HR for
the T risk allele carriers=1.26; 95%CI 0.61 to 2.62; P=0.53). Decline
in pulmonary function at 2 years was not influenced by MUC5B rs35705950
(OR=0.95; 95%CI 0.44 to 2.05; P=0.89), irrespective of the HRCT
pattern. Conclusion: In this study, the MUC5B rs35705950 promoter
variant did not influence transplant-free survival or decline in
pulmonary function in patients with RA-ILD. (c) 2021 Published by
Elsevier Inc.
ER -